Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.
Yuda ZhangFanxu ZengShixuan PengYangqian ChenWenjuan JiangZhan WangLi DengZhe HuangHaoyue QinHuan YanXing ZhangLin ZhangNong YangQian GongLiang ZengYong-Chang ZhangPublished in: Expert review of respiratory medicine (2023)
KRAS mutations have posed a significant challenge in the treatment of advanced non-small cell lung cancer (NSCLC) over the past few decades. However, the emergence of immunotherapy and KRAS inhibitors, such as Sotorasib (AMG 510) and Adagrasib (MRTX849), has marked a new era in cancer therapy. As more research and clinical trials continue, we anticipate the development of more effective treatment strategies and better options for lung cancer patients.